Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

4.68
+0.02000.43%
Post-market: 4.680.00000.00%19:38 EDT
Volume:475.31K
Turnover:2.24M
Market Cap:146.44M
PE:-1.13
High:4.81
Open:4.71
Low:4.67
Close:4.66
52wk High:50.40
52wk Low:4.54
Shares:31.29M
Float Shares:18.39M
Volume Ratio:0.74
T/O Rate:2.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.67
PE(LYR):-1.64

Loading ...

CARsgen Therapeutics Holdings Ltd. (2171) Receives a Sell from Goldman Sachs

TIPRANKS
·
Aug 20

Arcturus Therapeutics Earnings Call Balances Progress, Pressure

TIPRANKS
·
Aug 20

Revive Therapeutics Moves to Settle Trade Debt Through Share Issuance

TIPRANKS
·
Aug 20

Chemomab Therapeutics Files Q2 2026 Results and Updates SEC Registrations

TIPRANKS
·
Aug 19

Qyuns Therapeutics Swings to Interim Profit on Surging Licensing Revenue

TIPRANKS
·
Aug 19

Chemomab Therapeutics Q2 EPS $(0.24) Misses $(0.15) Estimate

Benzinga Earnings
·
Aug 19

CARsgen Therapeutics (SEHK:2171) Stock Carries Premium Valuation Despite Ongoing Losses

Simply Wall St.
·
Aug 19

Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
Aug 19

BioMarin Acquisition of Alesta Therapeutics Reinforces Growth Strategy; Whitney Ijem Reiterates Buy Rating and Maintains $114 Price Target

TIPRANKS
·
Aug 19

Press Release: Rakovina Therapeutics Announces Results from 2026 Annual General Meeting

Dow Jones
·
Aug 19

Cutia Therapeutics Sets Board Meeting to Approve Interim Results and Consider Dividend

TIPRANKS
·
Aug 19

Percheron Therapeutics Corrects Auditor Report Omission in FY2026 Annual Filing

TIPRANKS
·
Aug 19

Percheron Therapeutics Files ASX Corporate Governance Statement and Appendix 4G

TIPRANKS
·
Aug 19

Press Release: CARsgen Therapeutics Announces 2026 Interim Results

Dow Jones
·
Aug 19

TScan Therapeutics Faces Loss of Key Amgen Partnership

TIPRANKS
·
Aug 19

Tempest Therapeutics Adjourns Special Stockholder Meeting Again

TIPRANKS
·
Aug 19

CARsgen Therapeutics Holdings (SEHK:2171) Gains On CT0596 IND Clearance, But Is The Valuation Too Rich

Simply Wall St.
·
Aug 19

Analyst Reaffirms Buy on Rein Therapeutics With Unchanged $4 Target as Phase 2 IPF Trial Advances and Cash Runway Extends to 2028

TIPRANKS
·
Aug 19

Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026

GlobeNewswire
·
Aug 19

Intensity Therapeutics price target raised to $7 from $5 at H.C. Wainwright

TIPRANKS
·
Aug 19